Medline Inc. MDLN
39.47 USD -0.51 (-1.28%)
Regular-session close
39.48 +0.01 +0.03%
After hours · Nov 13, 6:15 PM ET
38.91 Day range 40.54
31.64 52-week range 49.99
- YTD
- -6.02%
- 1 year
- -3.73%
Benzinga news
benzinga.com UBS Maintains Buy on Medline, Raises Price Target to $49 UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $43 to $49.
benzinga.com Citigroup Maintains Buy on Medline, Raises Price Target to $47 Citigroup analyst Joanne Wuensch maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $45 to $47.
benzinga.com Leerink Partners Maintains Outperform on Medline, Raises Price Target to $46 Leerink Partners analyst Michael Cherny maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $43 to $46.- benzinga.com Evercore ISI Group Maintains Outperform on Medline, Raises Price Target to $44 Evercore ISI Group analyst Elizabeth Anderson maintains Medline (NASDAQ:MDLN) with a Outperform and raises the price target from $38 to $44.
benzinga.com Medline Q3 2026 Earnings Call Transcript Medline (NASDAQ:MDLN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
benzinga.com Medline Announces $1B Buyback Plan Medline Inc. ("Medline" or the "Company") (NASDAQ:MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of care, today announced its- benzinga.com Medline Q3 Adj. EPS $0.44 Beats $0.35 Estimate, Sales $7.856B Beat $7.723B Estimate Medline (NASDAQ:MDLN) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.35 by 25.71 percent. The company reported quarterly sales of $7.856 billion which…
benzinga.com ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test ARM Holdings headlines Wednesday’s reports, with investors looking for evidence that AI-related demand can support the chip designer after a sharp stock pullback. McDonald’s, Novo Nordisk, Uber…
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.- benzinga.com Mizuho Maintains Outperform on Medline, Lowers Price Target to $45 Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.
benzinga.com Barclays Maintains Overweight on Medline, Lowers Price Target to $43 Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $45 to $43.- benzinga.com UBS Maintains Buy on Medline, Lowers Price Target to $43 UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.
benzinga.com Medline Convenience Kits Impacted By Contamination In Recalled Becton Dickinson Products FDA alerts providers as Medline corrects convenience kits with recalled BD applicators due to sterility and contamination risks.
benzinga.com JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46 JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.
benzinga.com Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34 Wells Fargo analyst Stephen Baxter maintains Medline (NASDAQ:MDLN) with a Equal-Weight and lowers the price target from $45 to $34.
benzinga.com TD Cowen Maintains Buy on Medline, Lowers Price Target to $45 TD Cowen analyst Charles Rhyee maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $53 to $45.
benzinga.com RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46 RBC Capital analyst Ryan Halsted maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $53 to $46.- benzinga.com Truist Securities Maintains Buy on Medline, Lowers Price Target to $47 Truist Securities analyst Jailendra Singh maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $56 to $47.
- benzinga.com Evercore ISI Group Maintains Outperform on Medline, Lowers Price Target to $39 Evercore ISI Group analyst Elizabeth Anderson maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $39.
benzinga.com Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.- benzinga.com Medline Q2 Adj. EPS $0.50 Beats $0.32 Estimate, Sales $7.685B Beat $7.512B Estimate Medline (NASDAQ:MDLN) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.32 by 56.25 percent. The company reported quarterly sales of $7.685 billion which…
- benzinga.com Medline Strikes New Prime Vendor Agreement To Offer Access To Its Portfolio Of Medical-Surgical Products For Its Hospital, Physician Office Sites To Allina Health Medline (NASDAQ:MDLN) today announced that it signed a new Prime Vendor agreement with Allina Health, a healthcare system based in Minneapolis that provides care to communities across Minnesota and…
benzinga.com Jim Cramer: 'Go For' AST SpaceMobile, Power Plant Maker 'Too Speculative' Jim Cramer says Medline is "probably" the best IPO of 2026 and expects AST SpaceMobile to be profitable in two years.
benzinga.com Medline Distribution Center Fire Creates Near-Term Headwind: Analyst Medline (MDLN) faces near-term headwinds after a major CA warehouse fire. William Blair analysts break down the impact.- benzinga.com Baird Maintains Outperform on Medline, Lowers Price Target to $45 Baird analyst Eric Coldwell maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $57 to $45.
- benzinga.com FDA Sends Warning Letter To Medline Over CGMP Violations For Finished Pharmaceuticals On May 28 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medline-inc-724347-05282026
benzinga.com Barclays Maintains Overweight on Medline, Lowers Price Target to $45 Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $50 to $45.- benzinga.com Medline Announces That Medline Canada Has Signed Its First Prime Vendor Agreement In The Country And Is The First Medline Prime Vendor Relationship Outside The United States Medline (NASDAQ:MDLN) announced that Medline Canada has signed its first Prime Vendor agreement in the country and is the first Medline Prime Vendor relationship outside the United States. The…
- benzinga.com Medline Signs Prime Vendor Agreement With Rural Medical Services; Agreement Enables Access To Medline's Medical-Surgical Products And Supply Chain Solution Offerings Medline (NASDAQ:MDLN) today announced that it signed a new Prime Vendor agreement with Rural Medical Services Inc., a community-based, non-profit federally qualified health center (FQHC) based in…
- benzinga.com Medline Announces Secondary Public Offering Of 60M Shares Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi…
- benzinga.com BNP Paribas Maintains Neutral on Medline, Lowers Price Target to $40 BNP Paribas analyst Navann Ty maintains Medline (NASDAQ:MDLN) with a Neutral and lowers the price target from $49 to $40.
- benzinga.com Tigress Financial Maintains Buy on Medline, Raises Price Target to $62 Tigress Financial analyst Ivan Feinseth maintains Medline (NASDAQ:MDLN) with a Buy and raises the price target from $60 to $62.
- benzinga.com Citigroup Maintains Buy on Medline, Lowers Price Target to $55 Citigroup analyst Patrick Donnelly maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $60 to $55.
- benzinga.com Bernstein Maintains Outperform on Medline, Lowers Price Target to $54 Bernstein analyst Lee Hambright maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $56 to $54.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com FDA Announces Medline Recalls All Of Its Stock Keeping Units In Medline Branded Neuro Sponge Category With No Definite Market Re-Entry Date https://www.fda.gov/medical-devices/letters-health-care-providers/disruptions-availability-neurosurgical-patties-sponges-and-strips-letter-health-care-providers
benzinga.com Medline Q1 2026 Earnings Call: Complete Transcript - benzinga.com Medline Q1 EPS $0.33 Beats $0.23 Estimate, Sales $7.400B Beat $7.163B Estimate Medline (NASDAQ:MDLN) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.23 by 43.48 percent. The company reported quarterly sales of $7.400 billion which…
- benzinga.com FDA Recalls Several Medline Products https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=219163
- benzinga.com Medline Collaborates With Symbotic Over Deployment Of AI Robotics Technology Medline (NASDAQ:MDLN) announced a strategic agreement to implement next-generation warehouse automation from Symbotic, a leader in AI-enabled robotics technology, as part of the company's ongoing…
benzinga.com Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.
benzinga.com FDA Flags Quality System Lapses At Medline Facility Over Device Risks FDA warns Medline over device quality lapses, citing CAPA failures, contamination risks, and unresolved syringe disconnection issues.- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com Palantir, Tesla, And Applovin Are Among Top 10 Large Cap Losers Last Week (Dec. 29-Jan. 2): Are the Others in Your Portfolio? Last week's large-cap laggards were led by Regencell, AppLovin, and Palantir after big prior runs, while Tesla slipped on Q4 deliveries missing estimates amid Europe pressure, with additional…
benzinga.com Medline (MDLN) Stock Falls In After-Hours Trading Following 41% IPO Surge Medline shares fell in after-hours trading following its upsized IPO pricing at $29 per share.